Do analysts prefer MJN or FRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cronos Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Fennec Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00

Which has stronger earnings and valuation, MJN or FRX?

Cronos Group has higher earnings, but lower revenue than Fennec Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cronos Group N/A N/A N/A N/A N/A Fennec Pharmaceuticals C$51.00M 11.59 -C$800.44K -C$0.29 N/A

Does the media favor MJN or FRX?

In the previous week, Cronos Group and Cronos Group both had 1 articles in the media. Cronos Group's average media sentiment score of 0.67 beat Fennec Pharmaceuticals' score of 0.00 indicating that Cronos Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cronos Group 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fennec Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate CARA or FRX?

Given Cara Operations' higher possible upside, equities research analysts clearly believe Cara Operations is more favorable than Fennec Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cara Operations 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Fennec Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00

Which has stronger valuation & earnings, CARA or FRX?

Cara Operations has higher earnings, but lower revenue than Fennec Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cara Operations N/A N/A N/A N/A N/A Fennec Pharmaceuticals C$51.00M 11.59 -C$800.44K -C$0.29 N/A

Do analysts rate CRON or FRX?

Cronos Group presently has a consensus price target of C$4.92, suggesting a potential upside of 14.88%. Given Cronos Group's higher probable upside, equities research analysts plainly believe Cronos Group is more favorable than Fennec Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cronos Group 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Fennec Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00

Does the media favor CRON or FRX?

In the previous week, Cronos Group had 1 more articles in the media than Fennec Pharmaceuticals. MarketBeat recorded 2 mentions for Cronos Group and 1 mentions for Fennec Pharmaceuticals. Cronos Group's average media sentiment score of 0.47 beat Fennec Pharmaceuticals' score of 0.00 indicating that Cronos Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cronos Group 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Fennec Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer DHT.UN or FRX?

DRI Healthcare Trust currently has a consensus target price of C$25.20, suggesting a potential upside of 38.77%. Given DRI Healthcare Trust's higher probable upside, equities research analysts plainly believe DRI Healthcare Trust is more favorable than Fennec Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DRI Healthcare Trust 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Fennec Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00

Does the media prefer DHT.UN or FRX?

In the previous week, DRI Healthcare Trust had 4 more articles in the media than Fennec Pharmaceuticals. MarketBeat recorded 5 mentions for DRI Healthcare Trust and 1 mentions for Fennec Pharmaceuticals. DRI Healthcare Trust's average media sentiment score of 1.12 beat Fennec Pharmaceuticals' score of 0.00 indicating that DRI Healthcare Trust is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DRI Healthcare Trust 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fennec Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend FRX or GUD?

Knight Therapeutics has a consensus target price of C$9.50, indicating a potential upside of 2.70%. Given Knight Therapeutics' higher probable upside, analysts clearly believe Knight Therapeutics is more favorable than Fennec Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fennec Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00 Knight Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Does the media favor FRX or GUD?

In the previous week, Fennec Pharmaceuticals and Fennec Pharmaceuticals both had 1 articles in the media. Knight Therapeutics' average media sentiment score of 1.64 beat Fennec Pharmaceuticals' score of 0.00 indicating that Knight Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fennec Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Knight Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Fennec Pharmaceuticals (FRX) Competitors

C$17.01 0.00 (0.00%)

As of 08/13/2026 11:06 AM Eastern

Compare

FRX vs. MJN, CARA, CRON, DHT.UN, and GUD

Should you buy Fennec Pharmaceuticals stock or one of its competitors? Fennec Pharmaceuticals's main competitors and comparable companies include Cronos Group (MJN), Cara Operations (CARA), Cronos Group (CRON), DRI Healthcare Trust (DHT.UN), and Knight Therapeutics (GUD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Fennec Pharmaceuticals compare to Cronos Group?

Cronos Group (CVE:MJN) and Fennec Pharmaceuticals (TSE:FRX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.

14.5% of Fennec Pharmaceuticals shares are held by institutional investors. 16.2% of Fennec Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Cronos Group and Cronos Group both had 1 articles in the media. Cronos Group's average media sentiment score of 0.67 beat Fennec Pharmaceuticals' score of 0.00 indicating that Cronos Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cronos Group	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fennec Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cronos Group has a net margin of 0.00% compared to Fennec Pharmaceuticals' net margin of -6.21%. Cronos Group's return on equity of 0.00% beat Fennec Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cronos Group	N/A	N/A	N/A
Fennec Pharmaceuticals	-6.21%	-13.34%	8.88%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cronos Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Fennec Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00

Cronos Group has higher earnings, but lower revenue than Fennec Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cronos Group	N/A	N/A	N/A	N/A	N/A
Fennec Pharmaceuticals	C$51.00M	11.59	-C$800.44K	-C$0.29	N/A

Summary

Fennec Pharmaceuticals beats Cronos Group on 6 of the 9 factors compared between the two stocks.

How does Fennec Pharmaceuticals compare to Cara Operations?

Cara Operations (TSE:CARA) and Fennec Pharmaceuticals (TSE:FRX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

Cara Operations has a net margin of 0.00% compared to Fennec Pharmaceuticals' net margin of -6.21%. Cara Operations' return on equity of 0.00% beat Fennec Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cara Operations	N/A	N/A	N/A
Fennec Pharmaceuticals	-6.21%	-13.34%	8.88%

Cara Operations has higher earnings, but lower revenue than Fennec Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cara Operations	N/A	N/A	N/A	N/A	N/A
Fennec Pharmaceuticals	C$51.00M	11.59	-C$800.44K	-C$0.29	N/A

Given Cara Operations' higher possible upside, equities research analysts clearly believe Cara Operations is more favorable than Fennec Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cara Operations	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Fennec Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00

In the previous week, Fennec Pharmaceuticals had 1 more articles in the media than Cara Operations. MarketBeat recorded 1 mentions for Fennec Pharmaceuticals and 0 mentions for Cara Operations. Cara Operations' average media sentiment score of 0.00 equaled Fennec Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Cara Operations	Neutral
Fennec Pharmaceuticals	Neutral

14.5% of Fennec Pharmaceuticals shares are owned by institutional investors. 16.2% of Fennec Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Fennec Pharmaceuticals beats Cara Operations on 7 of the 10 factors compared between the two stocks.

How does Fennec Pharmaceuticals compare to Cronos Group?

Cronos Group (TSE:CRON) and Fennec Pharmaceuticals (TSE:FRX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and dividends.

Cronos Group has a beta of 1.13355, meaning that its stock price is 13% more volatile than the broader market. Comparatively, Fennec Pharmaceuticals has a beta of 3.548856, meaning that its stock price is 255% more volatile than the broader market.

Cronos Group has a net margin of 38.95% compared to Fennec Pharmaceuticals' net margin of -6.21%. Cronos Group's return on equity of 6.46% beat Fennec Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cronos Group	38.95%	6.46%	-3.73%
Fennec Pharmaceuticals	-6.21%	-13.34%	8.88%

Cronos Group presently has a consensus price target of C$4.92, suggesting a potential upside of 14.88%. Given Cronos Group's higher probable upside, equities research analysts plainly believe Cronos Group is more favorable than Fennec Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cronos Group	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Fennec Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00

Fennec Pharmaceuticals has lower revenue, but higher earnings than Cronos Group. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cronos Group	C$179.09M	8.80	-C$32.78M	C$0.19	22.53
Fennec Pharmaceuticals	C$51.00M	11.59	-C$800.44K	-C$0.29	N/A

4.4% of Cronos Group shares are owned by institutional investors. Comparatively, 14.5% of Fennec Pharmaceuticals shares are owned by institutional investors. 46.4% of Cronos Group shares are owned by company insiders. Comparatively, 16.2% of Fennec Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Cronos Group had 1 more articles in the media than Fennec Pharmaceuticals. MarketBeat recorded 2 mentions for Cronos Group and 1 mentions for Fennec Pharmaceuticals. Cronos Group's average media sentiment score of 0.47 beat Fennec Pharmaceuticals' score of 0.00 indicating that Cronos Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cronos Group	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Fennec Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Cronos Group beats Fennec Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Fennec Pharmaceuticals compare to DRI Healthcare Trust?

DRI Healthcare Trust (TSE:DHT.UN) and Fennec Pharmaceuticals (TSE:FRX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

DRI Healthcare Trust has a net margin of 5.02% compared to Fennec Pharmaceuticals' net margin of -6.21%. DRI Healthcare Trust's return on equity of 2.06% beat Fennec Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DRI Healthcare Trust	5.02%	2.06%	4.22%
Fennec Pharmaceuticals	-6.21%	-13.34%	8.88%

DRI Healthcare Trust currently has a consensus target price of C$25.20, suggesting a potential upside of 38.77%. Given DRI Healthcare Trust's higher probable upside, equities research analysts plainly believe DRI Healthcare Trust is more favorable than Fennec Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DRI Healthcare Trust	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.20
Fennec Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00

DRI Healthcare Trust has higher revenue and earnings than Fennec Pharmaceuticals. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than DRI Healthcare Trust, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DRI Healthcare Trust	C$172.34M	5.80	C$9.73M	-C$0.80	N/A
Fennec Pharmaceuticals	C$51.00M	11.59	-C$800.44K	-C$0.29	N/A

0.8% of DRI Healthcare Trust shares are held by institutional investors. Comparatively, 14.5% of Fennec Pharmaceuticals shares are held by institutional investors. 0.1% of DRI Healthcare Trust shares are held by company insiders. Comparatively, 16.2% of Fennec Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

DRI Healthcare Trust has a beta of 0.350693, indicating that its share price is 65% less volatile than the broader market. Comparatively, Fennec Pharmaceuticals has a beta of 3.548856, indicating that its share price is 255% more volatile than the broader market.

In the previous week, DRI Healthcare Trust had 4 more articles in the media than Fennec Pharmaceuticals. MarketBeat recorded 5 mentions for DRI Healthcare Trust and 1 mentions for Fennec Pharmaceuticals. DRI Healthcare Trust's average media sentiment score of 1.12 beat Fennec Pharmaceuticals' score of 0.00 indicating that DRI Healthcare Trust is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DRI Healthcare Trust	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fennec Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

DRI Healthcare Trust beats Fennec Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Fennec Pharmaceuticals compare to Knight Therapeutics?

Fennec Pharmaceuticals (TSE:FRX) and Knight Therapeutics (TSE:GUD) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, earnings, dividends, profitability, analyst recommendations, valuation and risk.

Knight Therapeutics has a net margin of 2.72% compared to Fennec Pharmaceuticals' net margin of -6.21%. Knight Therapeutics' return on equity of 1.91% beat Fennec Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fennec Pharmaceuticals	-6.21%	-13.34%	8.88%
Knight Therapeutics	2.72%	1.91%	0.51%

14.5% of Fennec Pharmaceuticals shares are held by institutional investors. Comparatively, 22.8% of Knight Therapeutics shares are held by institutional investors. 16.2% of Fennec Pharmaceuticals shares are held by insiders. Comparatively, 45.6% of Knight Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Fennec Pharmaceuticals has higher earnings, but lower revenue than Knight Therapeutics. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Knight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fennec Pharmaceuticals	C$51.00M	11.59	-C$800.44K	-C$0.29	N/A
Knight Therapeutics	C$547.31M	1.66	-C$30.73M	C$0.15	61.67

Fennec Pharmaceuticals has a beta of 3.548856, meaning that its share price is 255% more volatile than the broader market. Comparatively, Knight Therapeutics has a beta of -0.194384, meaning that its share price is 119% less volatile than the broader market.

Knight Therapeutics has a consensus target price of C$9.50, indicating a potential upside of 2.70%. Given Knight Therapeutics' higher probable upside, analysts clearly believe Knight Therapeutics is more favorable than Fennec Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fennec Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00
Knight Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Fennec Pharmaceuticals and Fennec Pharmaceuticals both had 1 articles in the media. Knight Therapeutics' average media sentiment score of 1.64 beat Fennec Pharmaceuticals' score of 0.00 indicating that Knight Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fennec Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Knight Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Knight Therapeutics beats Fennec Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

Get Fennec Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FRX vs. The Competition

Export

Metric	Fennec Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	TSE Exchange
Market Cap	C$590.88M	C$11.72B	C$6.98B	C$12.55B
Dividend Yield	2.02%	2.70%	2.58%	6.20%
P/E Ratio	-58.66	781.44	269.27	30.74
Price / Sales	11.59	748.15	597.31	9.76
Price / Cash	11.66	67.45	70.53	82.29
Price / Book	13.85	10.77	13.07	4.64
Net Income	-C$800.44K	C$2.78B	C$3.45B	C$299.09M
7 Day Performance	6.18%	-0.17%	0.74%	0.92%
1 Month Performance	15.01%	0.00%	1.40%	3.90%
1 Year Performance	49.74%	161.17%	67.03%	36.15%

Fennec Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FRX Fennec Pharmaceuticals	0.0454 of 5 stars	C$17.01 flat	N/A	+36.0%	C$590.88M	C$51.00M	N/A	10	Gap Up
MJN Cronos Group	N/A	C$12.15 -1.9%	N/A	+0.0%	C$1.73B	N/A	N/A	7,600
CARA Cara Operations	N/A	N/A	N/A	N/A	C$1.62B	N/A	N/A	80
CRON Cronos Group	2.9829 of 5 stars	C$4.32 flat	C$4.75 +10.0%	+21.8%	C$1.61B	C$159.54M	N/A	450	High Trading Volume
DHT.UN DRI Healthcare Trust	3.3647 of 5 stars	C$17.63 +3.0%	C$24.80 +40.7%	+21.9%	C$969.93M	C$163.77M	N/A	N/A	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (TSE:FRX) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Fennec Pharmaceuticals (FRX) Competitors

FRX vs. MJN, CARA, CRON, DHT.UN, and GUD

How does Fennec Pharmaceuticals compare to Cronos Group?

Summary

How does Fennec Pharmaceuticals compare to Cara Operations?

Summary

How does Fennec Pharmaceuticals compare to Cronos Group?

Summary

How does Fennec Pharmaceuticals compare to DRI Healthcare Trust?

Summary

How does Fennec Pharmaceuticals compare to Knight Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FRX vs. The Competition

Fennec Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Fennec Pharmaceuticals (FRX) Competitors

FRX vs. MJN, CARA, CRON, DHT.UN, and GUD

How does Fennec Pharmaceuticals compare to Cronos Group?

Do insiders & institutionals hold more shares of MJN or FRX?

Does the media favor MJN or FRX?

Is MJN or FRX more profitable?

Do analysts prefer MJN or FRX?

Which has stronger earnings and valuation, MJN or FRX?

Summary

How does Fennec Pharmaceuticals compare to Cara Operations?

Is CARA or FRX more profitable?

Which has stronger valuation & earnings, CARA or FRX?

Do analysts rate CARA or FRX?

Does the media prefer CARA or FRX?

Do insiders and institutionals hold more shares of CARA or FRX?

Summary

How does Fennec Pharmaceuticals compare to Cronos Group?

Which has more risk and volatility, CRON or FRX?

Is CRON or FRX more profitable?

Do analysts rate CRON or FRX?

Which has better earnings and valuation, CRON or FRX?

Do institutionals & insiders hold more shares of CRON or FRX?

Does the media favor CRON or FRX?

Summary

How does Fennec Pharmaceuticals compare to DRI Healthcare Trust?

Is DHT.UN or FRX more profitable?

Do analysts prefer DHT.UN or FRX?

Which has better valuation & earnings, DHT.UN or FRX?

Do institutionals and insiders hold more shares of DHT.UN or FRX?

Which has more risk and volatility, DHT.UN or FRX?

Does the media prefer DHT.UN or FRX?

Summary

How does Fennec Pharmaceuticals compare to Knight Therapeutics?

Is FRX or GUD more profitable?

Do institutionals & insiders have more ownership in FRX or GUD?

Which has stronger valuation and earnings, FRX or GUD?

Which has more risk and volatility, FRX or GUD?

Do analysts recommend FRX or GUD?

Does the media favor FRX or GUD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FRX vs. The Competition

Fennec Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools